<qa>  What is the risk of cardiac dysfunction?5. For subjects receiving doxorubicin, no concurrent use of inhibitors and inducers of CYP3A4, CYP2D6, andor P-gp or with trastuzumab due to increased risk of cardiac dysfunction 